Fig. 2From: Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD studyMean average best-corrected visual acuity (BCVA) change from baseline before and after cataract surgery. Results are shown for previously treated patients with cataract-related adverse events (AEs) in the dexamethasone intravitreal implant 0.7 mg group. Numbers in parentheses indicate number of patientsBack to article page